Opana ER abuse and thrombotic thrombocytopenic purpura (TTP)-like illness: a rising risk factor in illicit drug users.

Abstract

We report the case of a 22 year-old-woman who presented with upper extremity cellulitis secondary to an infiltration of illicit intravenous drug use. She confessed to the intravenous use of Opana ER (an extended release oral formulation of oxymorphone) which is an opioid drug approved only for oral use. She was found to have clinical evidence of profound thrombotic microangiopathy which resulted due to the intravenous use of Opana ER. She showed full clinical improvement after withholding drug and supportive clinical care. Recent report of Opana ER intravenous abuse was published from Tennessee county and has now been increasingly recognised as one of the causes of thrombocytopenia which mimicks clinically as thrombotic thrombocytopenic purpura. Physicians should be aware of this association as the lack of familiarity to this can pose serious management dilemmas for our patients (especially the polysubstance abusers).

• Authors: Aaysha Kapila, Lovely Chhabra, Vinod K Chaubey, Jeffery Summers
• Journal: BMJ case reports (BMJ Case Rep) Vol. 2014 (Mar 03 2014) ISSN: 1757-790X [Electronic] England
• PMID: 24591390 (Publication Type: Case Reports, Journal Article)

Chemical References

• Analgesics, Opioid
• Oxymorphone

Topics

• Analgesics, Opioid (adverse effects)
• Female
• Humans
• Opioid-Related Disorders (complications)
• Oxymorphone (adverse effects)
• Purpura, Thrombotic Thrombocytopenic (chemically induced, diagnosis)
• Substance Abuse, Intravenous (complications)
• Thrombotic Microangiopathies (chemically induced, diagnosis)
• Young Adult